ArticleCell proliferation2021
L-Se-methylselenocysteine sensitizes lung carcinoma to chemotherapy.
Article in Cell proliferation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring the Beneficial Effects of Se-Methylselenocysteine on GC-1/GC-2 Cells: From Cellular Uptake to Metabolic Pathway Regulation in Male Reproduction.Antioxidants (Basel, Switzerland) · 2026Article
- Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis.International journal of pharmaceutics: X · 2025Review
- Seleno-amino Acid Metabolism Reshapes the Tumor Microenvironment: from Cytotoxicity to Immunotherapy.International journal of biological sciences · 2024Review
- Preventing acute liver injury via hepatocyte-targeting nano-antioxidants.Cell proliferation · 2023Article
- Optimized methyl donor and reduced precursor degradation pathway for seleno-methylselenocysteine production in Bacillus subtilis.Microbial cell factories · 2023Article
- Establishing extended pluripotent stem cells from human urine cells.Cell & bioscience · 2023Article
- Selenium speciation-dependent cancer radiosensitization by induction of G2/M cell cycle arrest and apoptosis.Frontiers in bioengineering and biotechnology · 2023Article
- Selenium-Containing Agents Acting on Cancer-A New Hope?Pharmaceutics · 2022Review
- Review
- Homotypic targeting of immunomodulatory nanoparticles for enhanced peripheral and central immunity.Cell proliferation · 2022Article
- L-Se-methylselenocysteine sensitizes lung carcinoma to chemotherapy.Cell proliferation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesOrganic Selenium (Se) compounds such as L-Se-methylselenocysteine (L-SeMC/SeMC) have been employed as a class of anti-oxidant to protect normal tissues and organs from chemotherapy-induced systemic toxicity. However, their comprehensive effects on cancer cell proliferation and tumour progression remain elusive. MATERIALS AND
methodsCCK-8 assays were conducted to determine the viabilities of cancer cells after exposure to SeMC, chemotherapeutics or combined treatment. Intracellular reactive oxygen species (ROS) levels and lipid peroxidation levels were assessed via fluorescence staining. The efficacy of free drugs or drug-loaded hydrogel against tumour growth was evaluated in a xenograft mouse model.
resultsAmong tested cancer cells and normal cells, the A549 lung adenocarcinoma cells showed higher sensitivity to SeMC exposure. In addition, combined treatments with several types of chemotherapeutics induced synergistic lethality. SeMC promoted lipid peroxidation in A549 cells and thereby increased ROS generation. Significantly, the in vivo efficacy of combination therapy was largely potentiated by hydrogel-mediate drug delivery.
conclusionsOur study reveals the selectivity of SeMC in the inhibition of cancer cell proliferation and develops an efficient strategy for local combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.